体外膜氧合与临时心室辅助装置支持治疗心脏移植原发性移植物功能障碍的结局比较
单中心回顾性研究纳入2007至2015年597例心脏移植患者,其中44例(7.4%)发生严重原发性移植物功能障碍,分别接受临时心室辅助装置(VAD,n=17)或静脉-动脉体外膜氧合(VA-ECMO,n=27)支持。VA-ECMO组体外循环时间更短、支持时间更短、大出血和肾衰竭需肾脏替代治疗的发生率更低,但住院死亡率差异无统计学意义。
要点
- 严重PGD患者中,VA-ECMO较临时VAD支持体外循环时间更短、支持时间更短。
- VAD组大出血需开胸探查和肾衰竭需肾脏替代治疗的发生率显著高于VA-ECMO组。
- VA-ECMO组脱离支持比例更高(89% vs 59%),但住院死亡率差异无统计学意义。
核心结论
- 对于严重原发性移植物功能障碍,VA-ECMO支持较临时VAD支持可能带来更好的临床结局。
主要发现
- VAD组体外循环时间显著长于VA-ECMO组(323±86分钟 vs 216±65分钟,p<0.0001)。
- VAD组支持时间显著长于VA-ECMO组(14±17天 vs 5.2±3.9天,p=0.011)。
- VAD组大出血需开胸探查发生率显著高于VA-ECMO组(77% vs 30%,p=0.0047)。
- VAD组肾衰竭需肾脏替代治疗发生率显著高于VA-ECMO组(53% vs 11%,p=0.0045)。
- VAD组和VA-ECMO组住院死亡率分别为41%和19%(p=0.16),总体住院死亡率为27%。
临床怎么用
- 在严重PGD的机械循环支持选择上,VA-ECMO可能较临时VAD具有更优的早期结局,但需结合中心经验和患者具体情况个体化决策。
局限性
- 本研究为单中心回顾性研究,样本量较小(44例),组间比较的统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary graft dysfunction (PGD) is one of the most common causes of early death after orthotopic heart transplantation. Mechanical circulatory support devices are required for severe forms of PGD. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) and temporary ventricular assist device (VAD) support have both been reported to be useful for severe PGD. METHODS: Between January 2007 and December 2015, 597 patients received a heart transplant at our center. Of those, severe PGD developed in 44 patients (7.4%), and they received a continuous-flow external VAD (n = 17) or VA-ECMO (n = 27) support within 24 hours after transplant. We compared early and late outcomes between groups. RESULTS: Baseline characteristics were similar between groups. Implantation of the temporary VAD required longer cardiopulmonary bypass time compared with VA-ECMO (323 ± 86 minutes vs 216 ± 65 minutes, p < 0.0001). Patients who received a VAD were more likely to have longer support time (14 ± 17 days vs 5.2 ± 3.9 days, p = 0.011), a higher incidence of major bleeding requiring chest reexploration (77% vs 30%, p = 0.0047), and a higher incidence of renal failure requiring renal replacement therapy (53% vs 11%, p = 0.0045) after surgery. Overall hospital mortality was 27%. In-hospital mortality for VAD and VA-ECMO patients were 41% and 19%, respectively (p = 0.16). Ten patients (59%) were weaned from VAD support, and 24 (89%) were weaned from VA-ECMO support after adequate graft function recovery (p = 0.03). The 3-year post-transplant survival was 41% in the VAD group and 66% in the VA-ECMO group (p = 0.13). CONCLUSIONS: For severe PGD, support with VA-ECMO appears to result in better clinical outcomes compared with VAD.
引用
- Takeda K, Li B, Garan AR, et al. Improved outcomes from extracorporeal membrane oxygenation versus ventricular assist device temporary support of primary graft dysfunction in heart transplant. J Heart Lung Transplant. 2016. PMID: 28087104. doi:10.1016/j.healun.2016.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。